Results of the trial, involving 419 patients whose disease had progressed after using a so-called EGFR inhibitor drug such as AstraZeneca’s Iressa or Roche’s Tarceva, were presented at the World Conference on Lung Cancer and published online in the New England Journal of Medicine.